- World TB Day 2017: Advances, Challenges and Opportunities in the “End-TB” Era

Eskild Petersen, Markus Maeurer, Ben Marais, Giovanni Battista Migliori, Peter Mwaba, Francine Ntoumi, Cris Vilaplana, Kami Kim, Marco Schito, Alimuddin Zumla. p1–5
 
- Turning the tide against tuberculosis
Nesri Padayatchi, Naressa Naidu, Gerald Friedland, Kasavan Naidoo, Francesca Conradie, Kogieleum Naidoo, Max Roe O’Donnell. p6–9
 
- Tuberculosis eradication versus control
Marco Schito, Debra Hanna, Alimuddin Zumla. p10–13
 
- The risk of global epidemic replacement with drug-resistant Mycobacterium tuberculosis strains
Emma S. McBryde, Michael T. Meehan, Tan N. Doan, Romain Ragonnet, Ben J. Marais, Vanina Guernier, James M. Trauer. p14–20
 
 
Mishal Khan, Richard James, Neisha Sundaram, Shishi Wu, Mao Tang Eang, Saphonn Vonthanak, Richard Coker. p25–29
 
Rosella Centis, Lia D’Ambrosio, Alimuddin Zumla, Giovanni Battista Migliori. p30–33
 
- De-isolation of patients with pulmonary tuberculosis after start of treatment — clear, unequivocal guidelines are missing
Eskild Petersen, Faryal Khamis, Giovanni Battista Migliori, Julie Glerup Bay, Ben Marais, Christian Wejse, Alimuddin Zumla
p34–38
 
- Tuberculosis associated mortality in a prospective cohort in Sub Saharan Africa: Association with HIV and antiretroviral therapy
Tumaini J. Nagu, Said Aboud, Ramadhani Mwiru, Mecky I. Matee, Martin Rao, Wafaie W. Fawzi, Alimuddin Zumla, Markus J. Maeurer, Ferdinand Mugusi. p39–44
 
- The global dynamics of diabetes and tuberculosis: the impact of migration and policy implications
Enrico Girardi, Monica Sañé Schepisi, Delia Goletti, Matthew Bates, Peter Mwaba, Dorothy Yeboah-Manu, Francine Ntoumi, Fabrizio Palmieri, Markus Maeurer, Alimuddin Zumla, Giuseppe Ippolito. p45–53
 
- Tuberculosis and hypertension—a systematic review of the literature
Anneline Borchsenius Seegert, Frauke Rudolf, Christian Wejse, Dinesh Neupane. p54–61
 
- Health systems in the Republic of Congo: challenges and opportunities for implementing tuberculosis and HIV collaborative service, research, and training activities
Laure Stella Ghoma Linguissi, Luc Christian Gwom, Celine Nguefeu Nkenfou, Matthew Bates, Eskild Petersen, Alimuddin Zumla, Francine Ntoumi. p62–67
 
- Preventive therapy for latent tuberculosis infection—the promise and the challenges
G.J. Fox, C.C. Dobler, B.J. Marais, J.T. Denholm. p68–76
 
 
- Enhanced laboratory capacity development: a boost for effective tuberculosis control in resource-limited settings
Abraham Sunday Alabi, Afsatou Ndama Traoré, Marguerite Massinga Loembe, Ulysse Ateba-Ngoa, Matthias Frank, Ayola Akim Adegnika, Bertrand Lell, Jocelyn Mahoumbou, Carsten Köhler, Peter Gottfried Kremsner, Martin Peter Grobusch, on behalf of the CERMEL TB CapDev Group. p81–84
 
- European policies in the management of tuberculosis among migrants
Lia D’Ambrosio, Rosella Centis, Masoud Dara, Ivan Solovic, Giorgia Sulis, Alimuddin Zumla, Giovanni Battista Migliori. p85–89
 
 
- Impact of infectious disease epidemics on tuberculosis diagnostic, management, and prevention services: experiences and lessons from the 2014–2015 Ebola virus disease outbreak in West Africa
Rashid Ansumana, Samuel Keitell, Gregory M.T. Roberts, Francine Ntoumi, Eskild Petersen, Giuseppe Ippolito, Alimuddin Zumla
p101–104
 
 
- Quality of tuberculosis care in high burden countries: the urgent need to address gaps in the care cascade
Danielle Cazabon, Hannah Alsdurf, Srinath Satyanarayana, Ruvandhi Nathavitharana, Ramnath Subbaraman, Amrita Daftary, Madhukar Pai. p111–116
 
- Status of Tuberculosis services in Indian Prisons
Banuru Muralidhara Prasad, Badri Thapa, Sarabjit Singh Chadha, Anand Das, Entoor Ramachandra Babu, Subrat Mohanty, Sripriya Pandurangan, Jamhoih Tonsing. p117–121
 
 
Alimuddin Zumla, Isaac Darko Otchere, Gloria Ivy Mensah, Adwoa Asante-Poku, Florian Gehre, Markus Maeurer, Matthew Bates, Peter Mwaba, Francine Ntoumi, Dorothy Yeboah-Manu. p126–129
 
- Removing the bottleneck in whole genome sequencing of Mycobacterium tuberculosis for rapid drug resistance analysis: a call to action
Ruth McNerney, Taane G. Clark, Susana Campino, Camilla Rodrigues, David Dolinger, Liezel Smith, Andrea M. Cabibbe, Keertan Dheda, Marco Schito. p130–135
 
- Strong anti-Epstein Barr virus (EBV) or cytomegalovirus (CMV) cellular immune responses predict survival and a favourable response to anti-tuberculosis therapy
Tumaini Nagu, Said Aboud, Martin Rao, Mecky Matee, Rebecca Axelsson, Davide Valentini, Ferdinand Mugusi, Alimuddin Zumla, Markus Maeurer. p136–139
 
- Peptide microarray-based characterization of antibody responses to host proteins after bacille Calmette–Guérin vaccination
Davide Valentini, Martin Rao, Lalit Rane, Sayma Rahman, Rebecca Axelsson-Robertson, Rainer Heuchel, Matthias Löhr, Daniel Hoft, Susanna Brighenti, Alimuddin Zumla, Markus Maeurer. p140–154
 
- Immune recognition surface construction of Mycobacterium tuberculosis epitope-specific antibody responses in tuberculosis patients identified by peptide microarrays
Davide Valentini, Martin Rao, Giovanni Ferrara, Marc Perkins, Ernest Dodoo, Alimuddin Zumla, Markus Maeurer. p155–166
 
- Humoral immune profiling of mycobacterial antigen recognition in sarcoidosis and Löfgren’s syndrome using high-content peptide microarrays
Giovanni Ferrara, Davide Valentini, Martin Rao, Jan Wahlström, Johan Grunewald, Lars-Olof Larsson, Susanna Brighenti, Ernest Dodoo, Alimuddin Zumla, Markus Maeurer. p167–175
 
 
- Classifying new anti-tuberculosis drugs: rationale and future perspectives
Simon Tiberi, Anna Scardigli, Rosella Centis, Lia D’Ambrosio, Marcela Muñoz-Torrico, Miguel Ángel Salazar-Lezama, Antonio Spanevello, Dina Visca, Alimuddin Zumla, Giovanni Battista Migliori, Jose A. Caminero Luna. p181–184
 
 
- Applicability of the shorter ‘Bangladesh regimen’ in high multidrug-resistant tuberculosis settings
Giovanni Sotgiu, Simon Tiberi, Rosella Centis, Lia D’Ambrosio, Zhenia Fuentes, Alimuddin Zumla, Giovanni Battista Migliori
p190–193
 
- Pediatric multidrug-resistant tuberculosis clinical trials: challenges and opportunities
S.E. McAnaw, A.C. Hesseling, J.A. Seddon, K.E. Dooley, A.J. Garcia-Prats, S. Kim, H.E. Jenkins, H.S. Schaaf, T.R. Sterling, C.R. Horsburgh. p194–199
 
- Retrospective study of clinical and lesion characteristics of patients undergoing surgical treatment for Pulmonary Tuberculosis in GeorgiaSergo Vashakidze, Albert Despuig, Shota Gogishvili, Keti Nikolaishvili, Natalia Shubladze, Zaza Avaliani, Nestan Tukvadze, Martí Casals, Joan A. Caylà, Pere-Joan Cardona, Cristina Vilaplana. p200–207
 
Debra Hanna, Klaus Romero, Marco Schito. p208–211
 
- New tuberculosis drug leads from naturally occurring compounds
Diana Quan, Gayathri Nagalingam, Richard Payne, James A. Triccas. p212–220
 
- Anti-PD-1/PD-L1 therapy for infectious diseases: learning from the cancer paradigm
Martin Rao, Davide Valentini, Ernest Dodoo, Alimuddin Zumla, Markus Maeurer. p221–228
 
- Ultrasound for patients in a high HIV/tuberculosis prevalence setting: a needs assessment and review of focused applications for Sub-Saharan Africa
Tom Heller, Eric A. Mtemang’ombe, Michaëla A.M. Huson, Charlotte C. Heuvelings, Sabine Bélard, Saskia Janssen, Sam Phiri, Martin P. Grobusch. p229–236
 
- Imaging in extrapulmonary tuberculosis
Sanjay Gambhir, Mudalsha Ravina, Kasturi Rangan, Manish Dixit, Sukanta Barai, Jamshed Bomanji, the International Atomic Energy Agency Extra-pulmonary TB Consortium. p237–247
 
- Exploring tuberculosis by molecular tests on DNA isolated from smear microscopy slides
Niaina Rakotosamimanana, Marie Sylvianne Rabodoarivelo, Juan Carlos Palomino, Anandi Martin, Voahangy Rasolofo Razanamparany. p248–252
 
- A tuberculosis biomarker database: the key to novel TB diagnostics
Seda Yerlikaya, Tobias Broger, Emily MacLean, Madhukar Pai, Claudia M. Denkinger. p253–257
 
 
- Novel approaches to tuberculosis vaccine development
Stefan H.E. Kaufmann, January Weiner, C. Fordham von Reyn. p263–267
 
- Experimental animal modelling for TB vaccine development
Pere-Joan Cardona, Ann Williams. p268–273
 
- Mycobacterium tuberculosis proteins involved in cell wall lipid biosynthesis improve BCG vaccine efficacy in a murine TB model
Martin Rao, Nathalie Cadieux, Megan Fitzpatrick, Steven Reed, Sergei Arsenian, Davide Valentini, Shreemanta Parida, Ernest Dodoo, Alimuddin Zumla, Markus Maeurer. p274–282
 
 
Attachments:
Download this file (Alabi_Int_J_Infect_Dis_2017.pdf)Alabi_Int_J_Infect_Dis_2017.pdf[ ]464 kB
Download this file (Ansumana_Int_J_Infect_Dis_2017.pdf)Ansumana_Int_J_Infect_Dis_2017.pdf[ ]276 kB
Download this file (Cardona_Int_J_Infect_Dis_2017.pdf)Cardona_Int_J_Infect_Dis_2017.pdf[ ]421 kB
Download this file (Cazabon_Int_J_Infect_Dis_2017.pdf)Cazabon_Int_J_Infect_Dis_2017.pdf[ ]904 kB
Download this file (Centis_Int_J_Infect_Dis_2017.pdf)Centis_Int_J_Infect_Dis_2017.pdf[ ]997 kB
Download this file (Craig_Int_J_Infect_Dis_2017.pdf)Craig_Int_J_Infect_Dis_2017.pdf[ ]410 kB
Download this file (Donoghue_Int_J_Infect_Dis_2017.pdf)Donoghue_Int_J_Infect_Dis_2017.pdf[ ]323 kB
Download this file (D’Ambrosio_Int_J_Infect_Dis_2017.pdf)D’Ambrosio_Int_J_Infect_Dis_2017.pdf[ ]779 kB
Download this file (Ferrara_Int_J_Infect_Dis_2017.pdf)Ferrara_Int_J_Infect_Dis_2017.pdf[ ]1144 kB
Download this file (Fox_Int_J_Infect_Dis_2017.pdf)Fox_Int_J_Infect_Dis_2017.pdf[ ]463 kB
Download this file (Frick_Int_J_Infect_Dis_2017.pdf)Frick_Int_J_Infect_Dis_2017.pdf[ ]628 kB
Download this file (Girardi_Int_J_Infect_Dis_2017.pdf)Girardi_Int_J_Infect_Dis_2017.pdf[ ]545 kB
Download this file (Hanna_Int_J_Infect_Dis_2017.pdf)Hanna_Int_J_Infect_Dis_2017.pdf[ ]869 kB
Download this file (Heller_Int_J_Infect_Dis_2017.pdf)Heller_Int_J_Infect_Dis_2017.pdf[ ]568 kB
Download this file (Heuvelings_Int_J_Infect_Dis_2017.pdf)Heuvelings_Int_J_Infect_Dis_2017.pdf[ ]370 kB
Download this file (Kaufmann_Int_J_Infect_Dis_2017.pdf)Kaufmann_Int_J_Infect_Dis_2017.pdf[ ]592 kB
Download this file (Kendall_Int_J_Infect_Dis_2017.pdf)Kendall_Int_J_Infect_Dis_2017.pdf[ ]518 kB
Download this file (Khan_Int_J_Infect_Dis_2017.pdf)Khan_Int_J_Infect_Dis_2017.pdf[ ]832 kB
Download this file (Marais_Int_J_Infect_Dis_2017.pdf)Marais_Int_J_Infect_Dis_2017.pdf[ ]275 kB
Download this file (McAnaw_Int_J_Infect_Dis_2017.pdf)McAnaw_Int_J_Infect_Dis_2017.pdf[ ]364 kB
Download this file (McBryde_Int_J_Infect_Dis_2017.pdf)McBryde_Int_J_Infect_Dis_2017.pdf[ ]1257 kB
Download this file (McNerney_Int_J_Infect_Dis_2017.pdf)McNerney_Int_J_Infect_Dis_2017.pdf[ ]308 kB
Download this file (Nagu2_Int_J_Infect_Dis_2017.pdf)Nagu2_Int_J_Infect_Dis_2017.pdf[ ]640 kB
Download this file (Nagu_Int_J_Infect_Dis_2017.pdf)Nagu_Int_J_Infect_Dis_2017.pdf[ ]382 kB
Download this file (Petersen2_Int_J_Infect_Dis_2017.pdf)Petersen2_Int_J_Infect_Dis_2017.pdf[ ]363 kB
Download this file (Petersen_Int_J_Infect_Dis_2017.pdf)Petersen_Int_J_Infect_Dis_2017.pdf[ ]322 kB
Download this file (Prasad_Int_J_Infect_Dis_2017.pdf)Prasad_Int_J_Infect_Dis_2017.pdf[ ]673 kB
Download this file (Quan_Int_J_Infect_Dis_2017.pdf)Quan_Int_J_Infect_Dis_2017.pdf[ ]753 kB
Download this file (Rakotosamimanana_Int_J_Infect_Dis_2017.pdf)Rakotosamimanana_Int_J_Infect_Dis_2017.pdf[ ]289 kB
Download this file (Rao2_Int_J_Infect_Dis_2017.pdf)Rao2_Int_J_Infect_Dis_2017.pdf[ ]1199 kB
Download this file (Rao_Int_J_Infect_Dis_2017.pdf)Rao_Int_J_Infect_Dis_2017.pdf[ ]982 kB
Download this file (Schito_Int_J_Infect_Dis_2017.pdf)Schito_Int_J_Infect_Dis_2017.pdf[ ]652 kB
Download this file (Sotgiu_Int_J_Infect_Dis_2017.pdf)Sotgiu_Int_J_Infect_Dis_2017.pdf[ ]267 kB
Download this file (Tiberi_Int_J_Infect_Dis_2017.pdf)Tiberi_Int_J_Infect_Dis_2017.pdf[ ]268 kB
Download this file (Vashakidze_Int_J_Infect_Dis_2017.pdf)Vashakidze_Int_J_Infect_Dis_2017.pdf[ ]1643 kB
Download this file (Villaplana_Int_J_Infect_Dis_2017.pdf)Villaplana_Int_J_Infect_Dis_2017.pdf[ ]251 kB
Download this file (Weiner_Int_J_Infect_Dis_2017.pdf)Weiner_Int_J_Infect_Dis_2017.pdf[ ]614 kB
Download this file (Wu_Int_J_Infect_Dis_2017.pdf)Wu_Int_J_Infect_Dis_2017.pdf[ ]559 kB
Download this file (Yerlikaya_Int_J_Infect_Dis_2017.pdf)Yerlikaya_Int_J_Infect_Dis_2017.pdf[ ]489 kB
Download this file (Zumla_Int_J_Infect_Dis_2017.pdf)Zumla_Int_J_Infect_Dis_2017.pdf[ ]269 kB

Rita M. Zorzenon dos Santos, Ana Amador, Wayner V. de Souza, Maria Fatima P. M. de Albuquerque, Silvina Ponce Dawson, Antonio Ruffino-Netto, Carlos R. Zárate-Bladés, Celio L. Silva

Abstract


Background: Detailed analysis of the dynamic interactions among biological, environmental, social, and economic factors that favour the spread of certain diseases is extremely useful for designing effective control strategies. Diseases like tuberculosis that kills somebody every 15 seconds in the world, require methods that take into account the disease dynamics to design truly efficient control and surveillance strategies. The usual and well established statistical approaches provide insights into the cause-effect relationships that favour disease transmission but they only estimate risk areas, spatial or temporal trends. Here we introduce a novel approach that allows figuring out the dynamical behaviour of the disease spreading. This information can subsequently be used to validate mathematical models of the dissemination process from which the underlying mechanisms that are responsible for this spreading could be inferred.

Attachments:
Download this file (1224_Dynamic_Analysis.pdf)1224_Dynamic_Analysis.pdf[ ]594 kB
Leia mais...

Christian Lienhardt, Sharlette V. Cook, Marcos Burgos, Victoria Yorke-Edwards, Leen Rigouts, Gladys Anyo, Sang-Jae Kim, Amina Jindani, Don A. Enarson, Andrew J. Nunn, for the Study C Trial Group

Context Fixed-dose combinations (FDCs) of drugs for treatment of tuberculosis have been advocated to prevent the emergence of drug resistance.


Objective To assess the efficacy and safety of a 4-drug FDC for the treatment of tuberculosis.

Attachments:
Download this file (1381_1415.full.pdf)Efficacy and Safety of a 4-Drug Fixed-Dose Combination Regimen Compared With Sep[The Study C Randomized Controlled Trial]304 kB
Leia mais...

Brazilian and American scientists have demonstrated that a compound known as P-Mapa is active against Mycobacterium tuberculosis in vivo. These results they say may pave the way for the use of this compound in the treatment of tuberculosis and other infectious diseases on humans.

P-Mapa is the acronym for a compound chemically classified as the proteinaceous aggregate of ammonium and magnesium phospholinoleate-palmitoleate anhydride. It has been developed since the 1990s by a group of Brazilian, Chilean and American scientists led by the non-profit research network Farmabrasilis. Tests on TB and other pathogens were carried out in the US by the National Institute of Allergy and Infectious Diseases (NIAID) teams.

Leia mais...

Sobre a REDE-TB

A Rede Brasileira de Pesquisa em Tuberculose (REDE-TB) é uma Organização Não Governamental (ONG) de direito privado sem fins lucrativos, preocupada em auxiliar no desenvolvimento não só de novos medicamentos, novas vacinas, novos testes diagnósticos e novas estratégias de controle de TB, mas também na validação dessas inovações tecnológicas, antes de sua comercialização no país e/ou de sua implementação nos Programa de Controle de TB no País.


bt2

Contato

E-mail: redetb.rp@gmail.com

Tel: +55 (21)3938 - 2426
Tel/ Fax: +55 (21)3938 - 2431.

Endereço: Avenida Carlos Chagas Filho, 791, Cidade Universitária - Ilha do Fundão, Rio de Janeiro, RJ - Brasil. CEP: 21941-904

Assine a newsletter da REDE-TB

Curta REDE-TB no Facebook